Skip to search formSkip to main contentSkip to account menu

BMS 214662

Known as: BMS-214662, BMS214662, FTI BMS 214662 
A nonsedating benzodiazepine derivative with potential antineoplastic activity. Farnesyltransferase inhibitor BMS-214662 inhibits the enzyme… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
Chronic myeloid leukemia (CML), a hematopoietic stem-cell disorder, cannot be eradicated by conventional chemotherapy or the… 
Highly Cited
2005
Highly Cited
2005
Lonafarnib (SCH66336) is a farnesyl transferase inhibitor (FTI) that inhibits the post-translational lipid modification of H-Ras… 
Highly Cited
2002
Highly Cited
2002
The development of chronic myeloid leukemia (CML) is dependent on the deregulated tyrosine kinase of the oncoprotein BCR-ABL… 
Highly Cited
2002
Highly Cited
2002
Inflammatory breast carcinoma (IBC) is a highly aggressive form of locally advanced breast cancer that has the ability to invade… 
Highly Cited
2001
Highly Cited
2001
BMS-214662 is a potent and selective inhibitor of farnesyltransferase (FTI). In rodent fibroblasts transformed by oncogenes, BMS… 
Highly Cited
2001
Highly Cited
2001
BCR/ABL, the oncoprotein responsible for chronic myeloid leukemia (CML), transforms hematopoietic cells through both Ras… 
Highly Cited
2000
Highly Cited
2000
Continuing structure-activity studies were performed on the 2,3,4, 5-tetrahydro-1-(imidazol-4-ylalkyl)-1,4-benzodiazepine… 
Highly Cited
2000
Highly Cited
2000
Farnesyltransferase inhibitors (FTIs) were developed to target abnormal signaling pathways that are commonly activated in… 
Highly Cited
1997
Highly Cited
1997
Protein farnesyltransferase inhibitors (FTIs) inhibit Ras transformation and Ras-dependent tumor cell growth, but the biological… 
Highly Cited
1997
Highly Cited
1997
Farnesyl transferase inhibitors (FTIs) are a novel class of antitumor drugs that block the oncogenic activity of Ras. Because…